153 related articles for article (PubMed ID: 29660901)
1. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay.
Liberati D; Marzinotto I; Brigatti C; Dugnani E; Pasquale V; Reni M; Balzano G; Falconi M; Piemonti L; Lampasona V
Cancer Biomark; 2018; 22(2):351-357. PubMed ID: 29660901
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.
Capello M; Cappello P; Linty FC; Chiarle R; Sperduti I; Novarino A; Salacone P; Mandili G; Naccarati A; Sacerdote C; Beghelli S; Bersani S; Barbi S; Bassi C; Scarpa A; Nisticò P; Giovarelli M; Vineis P; Milella M; Novelli F
J Hematol Oncol; 2013 Sep; 6():67. PubMed ID: 24010981
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of autoantibodies to Ezrin and pancreatic cancer risk.
Sun Y; Wu J; Cai H; Wang S; Liu Q; Blot WJ; Shu XO; Cai Q
Cancer Causes Control; 2016 Jun; 27(6):831-5. PubMed ID: 27146838
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody signature in human ductal pancreatic adenocarcinoma.
Tomaino B; Cappello P; Capello M; Fredolini C; Ponzetto A; Novarino A; Ciuffreda L; Bertetto O; De Angelis C; Gaia E; Salacone P; Milella M; Nisticò P; Alessio M; Chiarle R; Giuffrida MG; Giovarelli M; Novelli F
J Proteome Res; 2007 Oct; 6(10):4025-31. PubMed ID: 17824682
[TBL] [Abstract][Full Text] [Related]
5. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
6. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer.
Tomaino B; Cappello P; Capello M; Fredolini C; Sperduti I; Migliorini P; Salacone P; Novarino A; Giacobino A; Ciuffreda L; Alessio M; Nisticò P; Scarpa A; Pederzoli P; Zhou W; Petricoin Iii EF; Liotta LA; Giovarelli M; Milella M; Novelli F
J Proteome Res; 2011 Jan; 10(1):105-12. PubMed ID: 20455595
[TBL] [Abstract][Full Text] [Related]
7. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
8. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels.
Seifert AM; Reiche C; Heiduk M; Tannert A; Meinecke AC; Baier S; von Renesse J; Kahlert C; Distler M; Welsch T; Reissfelder C; Aust DE; Miller G; Weitz J; Seifert L
Oncogene; 2020 Apr; 39(15):3102-3113. PubMed ID: 32055023
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of circulating LAPTM4B-35 in pancreatic ductal adenocarcinoma.
Yang Z; Senninger N; Flammang I; Ye Q; Dhayat SA
J Cancer Res Clin Oncol; 2019 May; 145(5):1165-1178. PubMed ID: 30778748
[TBL] [Abstract][Full Text] [Related]
10. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification.
Lindgaard SC; Sztupinszki Z; Maag E; Chen IM; Johansen AZ; Jensen BV; Bojesen SE; Nielsen DL; Hansen CP; Hasselby JP; Nielsen KR; Szallasi Z; Johansen JS
Clin Cancer Res; 2021 May; 27(9):2592-2603. PubMed ID: 33737308
[TBL] [Abstract][Full Text] [Related]
11. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
12. Serum EpCAM expression in pancreatic cancer.
Gebauer F; Struck L; Tachezy M; Vashist Y; Wicklein D; Schumacher U; Izbicki JR; Bockhorn M
Anticancer Res; 2014 Sep; 34(9):4741-6. PubMed ID: 25202052
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies.
Sikora K; Bedin C; Vicentini C; Malpeli G; D'Angelo E; Sperandio N; Lawlor RT; Bassi C; Tortora G; Nitti D; Agostini M; Fassan M; Scarpa A
Int J Biol Markers; 2015 Feb; 30(1):e136-41. PubMed ID: 24832178
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Value of Autoantibodies against Ezrin in Esophageal Squamous Cell Carcinoma.
Li L; Liu M; Lin JB; Hong XB; Chen WX; Guo H; Xu LY; Xu YW; Li EM; Peng YH
Dis Markers; 2017; 2017():2534648. PubMed ID: 28298808
[TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
17. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
19. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
20. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.
Takehara A; Eguchi H; Ohigashi H; Ishikawa O; Kasugai T; Hosokawa M; Katagiri T; Nakamura Y; Nakagawa H
Cancer Sci; 2006 Nov; 97(11):1191-7. PubMed ID: 16918991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
